Telix shares surge after revenue lifts 11% in first quarter
Make us a preferred source
Make us a preferred source on Google
The news: Telix Pharmaceuticals shares jumped after reporting an unaudited group revenue increase of 11% quarter on quarter to USD230 million ($332.6 million) for Q1 2026.
The numbers: At 10:32am AEST, shares in Telix had lifted 6.4% to $13.78.
Precision medicine unaudited revenue lifted 16% quarter on quarter to USD186 million amid strong growth for the Illuccix and Gozellix products.
Telix Pharmaceuticals also reaffirmed FY26 revenue guidance of between USD950 million and USD970 million.
The context: During the period, its prostate cancer therapy candidate TLX591-Tx new drug application was accepted in China by the National Medical Products Administration and progressed through a global phase three study.
For Telix’s brain cancer imaging candidate TLX101-Px, a new drug application was resubmitted to the US Food and Drug Administration for Pixclara and a market authorisation application was filed in Europe for Pixlumi.
What they said: “Growth accelerated across our Precision Medicine business in the first quarter, with U.S. dose volumes increasing 5% quarter-over-quarter,” Telix managing director and group CEO Christian Behrenbruch said.
“This performance reflects the growing uptake of Gozellix alongside Illuccix, contributing to market share gains underpinned by disciplined sales execution and pricing, and high-quality service delivery despite extreme North American weather conditions, an advantage of the pharmacy distribution model.”
The source: ASX
